David Nassif
Net worth: 3 M $ as of 2026-05-30
Net worth: 3 M $ as of 2026-05-30
David W.
Nassif currently works at Sio Gene Therapies, Inc., as CEO, CFO, Director, CAO & General Counsel from 2022 and Pharvaris NV, as Chief Financial & Legal Officer, Secretary from 2024.
Mr. Nassif also formerly worked at Cypros Pharmaceutical Corp., as Chief Financial Officer & Senior Vice President from 1993 to 1999, Zaldiva, Inc., as Chief Financial Officer, Zogenix, Inc., as CFO, Secretary, Treasurer & Executive VP in 2010, Amphastar Pharmaceuticals, Inc., as Chief Financial Officer & SVP-Global Licensing from 2002 to 2006, RealAge, Inc., as Chief Financial Officer & Senior Vice President from 2000 to 2001, Strategic Consulting Services, as Principal from 2001 to 2002, Strategic Consulting Services, as Principal in 2006, Histogen, Inc., as President & Chief Financial Officer from 2011 to 2014, SteadyMed Ltd., as Chief Financial Officer & Executive Vice President from 2015 to 2019, and Axovant Sciences, Inc., as Chief Financial Officer from 2019 to 2020.
Mr. Nassif received his undergraduate degree from the University of Virginia and graduate degree from the University of Virginia School of Law.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PHARVARIS N.V. 0.16% | 2026-05-20 | 113,925 ( 0.16% ) | 3 M $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| SIO GENE THERAPIES INC. | Chief Executive Officer | 2022-01-30 |
| PHARVARIS N.V. | Director of Finance/CFO | 2024-04-14 |
| Companies | Position | End |
|---|---|---|
Axovant Sciences, Inc.
Axovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Director of Finance/CFO | 2020-11-30 |
| STEADYMED LTD | Director of Finance/CFO | 2019-06-29 |
Histogen, Inc. /Old/
Histogen, Inc. /Old/ Medical/Nursing ServicesHealth Services Researches, develops, manufactures and sells medicines | Director of Finance/CFO | 2014-08-31 |
| ZOGENIX, INC. | Director of Finance/CFO | 2010-03-01 |
Strategic Consulting Services | Corporate Officer/Principal | 2006-09-30 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 13 |
|---|---|
Cypros Pharmaceutical Corp.
Cypros Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceuticals for the critical care market | Health Technology |
Zaldiva, Inc.
Zaldiva, Inc. Specialty StoresRetail Trade Sells comic books, toys and collectible items | Retail Trade |
Zogenix, Inc.
Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets medicines | Health Technology |
University of Virginia
University of Virginia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures proprietary injectable and inhalation products | Health Technology |
RealAge, Inc.
RealAge, Inc. Internet Software/ServicesTechnology Services Provides personalized health information services | Technology Services |
Strategic Consulting Services | |
Histogen, Inc. /Old/
Histogen, Inc. /Old/ Medical/Nursing ServicesHealth Services Researches, develops, manufactures and sells medicines | Health Services |
University of Virginia School of Law
University of Virginia School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SteadyMed Ltd.
SteadyMed Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research, development, and manufacture of pharmaceutical products | Health Technology |
Sio Gene Therapies, Inc.
Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops gene therapies to treat neurodegenerative diseases | Health Technology |
Axovant Sciences, Inc.
Axovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
Pharvaris NV
Pharvaris NV BiotechnologyHealth Technology Develops and commercializes oral bradykinin B2 receptor antagonists | Health Technology |
Select your edition
All financial news and data tailored to specific country editions